Peripheral T cell receptor diversity is associated with clinical outcomes following ipilimumab treatment in metastatic melanoma by Michael A. Postow et al.
Postow et al. Journal for ImmunoTherapy of Cancer  (2015) 3:23 
DOI 10.1186/s40425-015-0070-4SHORT REPORT Open AccessPeripheral T cell receptor diversity is associated
with clinical outcomes following ipilimumab
treatment in metastatic melanoma
Michael A. Postow1,2,5*, Manuarii Manuel3, Phillip Wong4, Jianda Yuan4, Zhiwan Dong4, Cailian Liu4, Solène Perez3,
Isabelle Tanneau3, Marlène Noel3, Anaïs Courtier3, Nicolas Pasqual3 and Jedd D. Wolchok1,2Abstract
Background: Ipilimumab improves overall survival in a subset of patients with metastatic melanoma. Peripheral
blood T cell receptor (TCR) repertoire diversity has been associated with favorable outcomes in patients with
cancer, but its relevance as a biomarker for ipilimumab outcomes remains unknown.
Findings: In this pilot study, we analyzed the pre-treatment peripheral blood TCR repertoire in 12 patients with
metastatic melanoma who received ipilimumab at 3 mg/kg (clinical benefit, n = 4; no clinical benefit, n = 8). TCR
diversity was evaluated using a polymerase chain reaction assay which measures TCR combinatorial diversity between
V and J genes from genomic DNA. TCR repertoire diversity was studied through richness (observed V-J rearrangements)
and evenness (similarity between the frequencies of specific V-J rearrangements). The Wilcoxon rank sum test was used
to compare patients with clinical benefit and those without. Association with benefit in a dichotomized analysis was
assessed through a Fisher’s exact test. Overall survival was studied through log-rank analysis.
There was a significant difference in richness (p = 0.033) and evenness (p = 0.028) between patients with and without
clinical benefit. Dichotomized analysis showed that none of the patients with low richness (n = 0/5, p = 0.081) nor low
evenness (n = 0/7, p = 0.01) achieved clinical benefit. There were no significant differences in overall survival.
Conclusions: In this small group of patients, baseline TCR diversity in the peripheral blood was associated with clinical
outcomes. Further investigation is ongoing in larger cohorts of patients to explore these preliminary findings and
determine whether TCR diversity can be used as a predictive biomarker in cancer immunotherapy.Background
Antibodies that block immunologic checkpoints can
result in long-lasting benefit for patients with many dif-
ferent malignancies. Cytotoxic T lymphocyte antigen 4
(CTLA-4) was the first immunologic checkpoint to be
clinically targeted, and the anti-CTLA-4 antibody, ipili-
mumab, has been shown to improve overall survival in
a subset of patients [1, 2]. Identifying which patients
are most likely to benefit from ipilimumab remains an
active area of investigation.
Since ipilimumab is believed to exert its antitumor
effects through T cells, a number of studies have* Correspondence: postowm@mskcc.org
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unless otherwise stated.investigated T lymphocyte populations and correlated
immunologic changes with patient outcomes. Increases in
the absolute lymphocyte count and markers of activation
such as inducible co-stimulator (ICOS) on CD4+ T cells
have been shown to be pharmacodynamic biomarkers of
ipilimumab that correlate with overall survival [3-7].
Other investigations have focused on the peripheral blood
T-cell receptor (TCR) repertoire and have shown that
CTLA-4 blockade diversifies the TCR repertoire [8]. In
another study, maintenance of high-frequency TCR clono-
types during CTLA-4 blockade was associated with im-
proved overall survival [9].
To better determine whether the pre-treatment TCR
repertoire diversity was associated with clinical out-
comes following ipilimumab, we conducted a pilot study
of 12 patients with metastatic melanoma treated with
ipilimumab. Since a diverse TCR repertoire may increase. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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is present and has been associated with favorable out-
comes in patients with other malignancies such as breast
cancer [10], we hypothesized that the combinatorial diver-
sity of the TCR repertoire would be relevant to clinical
outcomes following ipilimumab.Findings
Patients and treatment
Twelve patients with metastatic melanoma who were
treated with ipilimumab were selected for inclusion in
this analysis based upon sample availability and annotated
clinical data. Clinical benefit was determined by evidence
of tumor burden reduction or prolonged stable disease
lasting at least 9 months following initiation of ipilimu-
mab. Eight patients had no apparent clinical benefit from
ipilimumab, and four patients had clinical benefit. All
patients received ipilimumab at 3 mg/kg as per standard
of care outside of a clinical trial. All patients provided
informed consent to an institutional review board (IRB)
approved correlative blood drawing research protocol
prior to the collection of peripheral blood (Memorial
Sloan Kettering Cancer Center IRB # 00-144).Assessment of T cell receptor repertoire combinatorial
diversity
Peripheral blood was collected and stored as previously
described [11]. T cell receptor (TCR) diversity was evalu-
ated by authors blinded to clinical outcome using the
ImmunTraCkeR® test (ImmunID), a multiplex polymerase
chain reaction (PCR) assay which measures combinatorial
diversity of the TCR beta chain. Genomic DNA was ex-
tracted from blood clots using the QIAamp DNA Blood
Mini Kit (Qiagen) and concentrated using Amicon Ultra-
0.5 mL Centrifugal Filters (EMD Millipore). Multiplex
PCR was performed using an upstream primer specific for
all functional members of a given V family and a down-
stream primer specific for a J segment. This assay allows
the simultaneous detection of all TRBV–TRBJ rearrange-
ments covering 100 % of the possible combinatorial rear-
rangements (based on the international ImMunoGeneTics
information system®, IMGT®, http://www.imgt.org). PCR
products were separated by microfluidic migration
(Labchip GX, Perkin Elmer) using a lab-on-a-chip (HT
DNA 12 K LabChip Kit, Perkin Elmer). All V–J1, J2, J3,
J4, Jn products were separated as a function of their
size with a maximum amplicon expected size of ~5 kb.
The Constel’ID® software (ImmunID) was used to
analyze the data produced during the microfluidic mi-
gration and to generate a three-dimensional immune
map. This map is composed of peaks of variable height
corresponding to the rearrangements actually observed
in one sample with the height of each peak dependingupon the frequency of a particular TCR rearrangement.
(Example patient shown in Additional file 1: Figure S1).
Two separate metrics were used to further characterize
the diversity of the TCR repertoire—richness and even-
ness. Richness reflects how many different V-J rear-
rangements are present and is defined as the ratio
(expressed as a percentage) between the number of ob-
served rearrangements in a sample and the number of
possible theoretical rearrangements between V families
and J genes. Evenness reflects how similar the frequen-
cies of V-J rearrangements are to each other. An even-
ness value for each patient in this study was calculated
as the ratio of how many rearrangements amongst the
most frequent were necessary to account for 50 % of
the global map intensity (cumulative sum of each rear-
rangement’s frequency) divided by the total number of
rearrangements present. High evenness corresponds to
V-J rearrangements evenly represented in terms of fre-
quency. Low evenness corresponds to a TCR repertoire
dominated by specific V-J rearrangements that may in-
dicate increased clonality.Hierarchical clustering
Similarity among patients’ baseline samples was assessed
based on correlation between TCR repertoires, using
each single V-J rearrangement contribution. Unsuper-
vised hierarchical clustering with multiscale bootstrap
resampling (n = 10,000) was then performed to group
the most similar samples in a dendrogram. The measure
of distance used for clustering was based on correlation
between immune profiles, using each single rearrange-
ment contribution. Ward method was employed as the
method of agglomeration. Approximately unbiased (AU)
probability values were calculated based on multiscale
bootstrap resampling.
Association of T cell receptor repertoire diversity
(richness and evenness) with clinical outcome
Both richness and evenness were compared as a continu-
ous variable between patients with and without clinical
benefit using a Wilcoxon rank sum test. A receiver operat-
ing characteristic (ROC) curve was used to determine a
possible threshold for dichotomized analysis (i.e. low vs.
high diversity richness/evenness). Association with benefit
in the low vs. high groups was assessed through a Fisher’s
exact test. Overall survival was studied through log-rank
analysis. Statistical analyses were performed using the R
software.
Patients and treatment
A total of twelve patients with stage IV melanoma were
included in this analysis as described in Table 1. All had
a Karnofsky Performance Status of 90-100 %. Only one





Median age (range) 57 (38-78) 67 (52-77)
Sex 1 female 3 female
3 male 5 male
M-stage 0 M1A 2 M1A
2 M1B 0 M1B
2 M1C 6 M1C
Median baseline LDH 156 211 (183-438)
Karnofsky Performance 90 (90-100) 90 (90-100)
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as indicated. There were no obviously apparent demo-
graphic differences between patients with and without
clinical benefit in this small, non-randomized dataset.
The median follow-up time for overall survival was
785 days.
Association of T cell receptor repertoire diversity with
clinical outcomes
Unsupervised hierarchical clustering that compared VJ
usage among all of the patients revealed that the four
patients with clinical benefit (green) had similar VJ usage
(Fig. 1). Four of the eight patients who did not achieve
clinical benefit (orange, right side of Fig. 1) also appeared
to cluster together. There were no obviously apparent
clinical differences between the four patients without
benefit who clustered separately (orange, left side of Fig. 1)
from the other four patients without benefit (orange, right
side of Fig. 1).
Based upon these findings from hierarchical clustering
analysis that revealed similarity in VJ usage among the
patients with clinical benefit, we next sought to evaluate
whether TCR diversity (richness and evenness) was asso-
ciated with clinical benefit. Patients who experienced
clinical benefit from ipilimumab had a higher degree of
richness as a continuous variable than patients who didFig. 1 Hierarchical clustering of 12 patients’ TCR repertoires using each sin
unbiased (AU) probability valuesnot achieve clinical benefit (Fig. 2, p = 0.033). To further
explore this finding of TCR repertoire richness, a ROC
curve was created, and a threshold of 85 % was selected
to dichotomize patients into “low vs. high” richness
groups (Additional file 2: Figure S2). None of the pa-
tients with “low” richness (n = 5) experienced clinical
benefit, but four out of the seven patients with “high”
richness experienced clinical benefit (p = 0.081). There
was no significant difference in overall survival between
patients with “low” vs. “high” richness (p = 0.218).
Patients who experienced clinical benefit from ipilimu-
mab had a higher degree of evenness as a continuous
variable compared to patients who did not achieve clin-
ical benefit (Fig. 3, p = 0.028). A ROC curve was created
for TCR repertoire evenness, and a threshold of 25 %
was selected to dichotomize patients into “low vs. high”
evenness groups (Additional file 3: Figure S3). None of
the patients with “low” evenness (n = 7, example patient
Additional file 4: Figure S4A) experienced clinical bene-
fit, whereas four out of the five patients with “high”
evenness (example patient Additional file 4: Figure S4B)
experienced clinical benefit (p = 0.01). There was no sig-
nificant difference in overall survival between patients
with “low” vs. “high” evenness (p = 0.26).
Discussion
In a small group of patients with advanced melanoma,
TCR diversity in the peripheral blood, as assessed by this
specific technology, prior to treatment with ipilimumab
was shown to correlate with clinical outcomes. Patients
who had clinical benefit had a higher degree of richness
and evenness in their baseline TCR repertoires than
patients who did not have clinical benefit. Our results
suggest that an immunologically diverse TCR repertoire
prior to treatment may be important to optimizing out-
comes with ipilimumab.
Prior studies have evaluated the diversity within the
TCR repertoire during treatment with CTLA-4 blockade
using next-generation sequencing platforms that sequence
the TCR complementarity determining region 3 (CDR3)gle V-J rearrangement contribution. Red values indicate approximately
Fig. 2 Patients who had clinical benefit had a higher degree of TCR
repertoire richness at baseline (p = 0.033)
Fig. 3 Patients who had clinical benefit had a higher degree of TCR
repertoire evenness at baseline (p = 0.028)
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treatment” changes in TCR diversity during CTLA-4
blockade which we could not investigate due to limited
sample availability [9, 12]. In contrast to our findings, one
of these prior studies found no association between base-
line TCR repertoire diversity and response to CTLA-4
blockade with tremelimumab [8]. It is unclear why our re-
sults differ, but differences in CTLA-4 blocking antibodies
(tremelimumab in [8] and ipilimumab in this study) and
differences in technology are possible explanations. Since
many different technologies are currently being investi-
gated to assess the TCR repertoire, until additional valid-
ation is obtained for each, it remains to be determined
which methodology will be the most robust for future
investigations.
Our study is inherently limited by its small size and
retrospective nature and is therefore considered hypoth-
esis generating. Since these patients were not treated on
clinical trials, rigorous tumor measurements such as
Response Evaluation Criteria in Solid Tumors (RECIST)
were not applied. Prior to the examination of TCR rep-
ertoire diversity, clinical benefit was determined inde-
pendently by study investigators who retrospectively
categorized patient outcomes based upon evidence of
tumor shrinkage or prolonged stable disease. The per-
ipheral blood TCR diversity data were then generated
by separate individuals who were blinded to the patients’
clinical outcomes.
Our findings showed that TCR diversity was associated
with clinical benefit but not overall survival. One pos-
sible explanation for this could be the long survival
times of some of the patients in the group without clin-
ical benefit to ipilimumab. For example, one patient who
was alive 785 days after initiating ipilimumab progressed
in the brain with oligometastatic disease that was suc-
cessfully treated with stereotactic radiosurgery. Another
patient with 991 days of survival after initiating ipilimu-
mab progressed on ipilimumab but achieved subsequent
benefit with an antibody that blocks the programmed
death ligand 1. It is also possible that the overall sample
size was too small to detect a statistically significant dif-
ference between TCR diversity and overall survival.
As this was a small cohort, the thresholds we estab-
lished for “low” vs. “high” richness and evenness groups
are considered exploratory. As additional patients are
studied, the sensitivity and specificity of various thresh-
olds will become more confidently established. Despite
the small sample size, the diversity of the TCR repertoire
(richness per continuous analysis and evenness per both
continuous and dichotomized analysis) was significantly
associated with ipilimumab benefit.
A baseline TCR repertoire containing many different
V-J rearrangements (richness) represented at evenly dis-
tributed frequencies (evenness) with no one particular
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cause it could indicate an increased likelihood that a
particular immunologically “relevant” antitumor T cell
population is present that, once released from suppres-
sion by CTLA-4 blockade, can expand and contribute
to a tumor response. A more diverse TCR repertoire
may also be reflective of better “immunologic health” in
general. A diverse TCR repertoire has previously been
shown to be associated with decreased infection risk
after allogeneic stem cell transplantation [13], and as
we have shown, now appears potentially relevant to
outcomes following ipilimumab. A large multicenter
study (Predict-ID Melanoma, France) for confirmation
of these preliminary findings and for evaluation of changes
in TCR repertoire during treatment is underway.
Additional files
Additional file 1: Figure S1. Example of a patient’s immune profile.
The X-Y axis reflects the presence of a particular V-J recombination event.
Richness is dependent upon the number of specific V-J rearrangements
present. The Z-axis reflects the frequency of a particular recombinant
which is used to calculate evenness.
Additional file 2: Figure S2. A threshold of 85 % was selected to
dichotomize patients into low and high richness groups based upon
sensitivity and specificity calculations.
Additional file 3: Figure S3. A threshold of 25 % was selected to
dichotomize patients into low and high evenness groups based upon
sensitivity and specificity calculations.
Additional file 4: Figure S4. An example patient with low evenness <25 %
(A) and high evenness ≥25 % (B).
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